Upfront. The Licensee shall pay Ascendis a one-time, non-refundable, upfront payment of Twenty Million US Dollars ($20,000,000) within [***] of the Effective Date. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Appears in 2 contracts
Sources: Exclusive Licence Agreement (Ascendis Pharma a/S), Exclusive Licence Agreement (Ascendis Pharma a/S)